Atovaquone and proguanil hydrochloride for prophylaxis of malaria

Journal of Travel Medicine

Volumn 6, Issue SUPPL. 1, 1999, Pages

  Shanks, G Dennis ^a   Kremsner, Peter G ^b   Sukwa, Thomas Y ^c   Van Der Berg, J Dirk ^d   Shapiro, Theresa A ^e   Scott, Trevor R ^f   Chulay, Jeffrey D ^f  

^a US Army Medical Research Unit Kenya   (Kenya)

^b ALBERT SCHWEITZER HOSPITAL   (Gabon)

^c Tropical Diseases Research Centre Ndola   (Zambia)

^d 1 Military Hospital   (South Africa)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; DOXYCYCLINE; FANSIDAR; MEFLOQUINE; PLACEBO; PRIMAQUINE; PROGUANIL;

ANTIBIOTIC PROPHYLAXIS; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COUGHING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; MYALGIA; PATIENT COMPLIANCE; PHOTOSENSITIVITY DISORDER; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VERTIGO;

ANIMALS; ANTIMALARIALS; ATOVAQUONE; CHEMOPREVENTION; DRUG COMBINATIONS; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PROGUANIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRAVEL; TREATMENT OUTCOME;

EID: 0033008595     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Spencer HC. Drug-resistant malaria - changing patterns mean difficult decisions. Trans R Soc Trop Med 1985; 79: 748-758.
2. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993; 341:1299-1303.
3. Weinke T, Trautmann M, Held T, et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 1991; 45:86-91.
4. Bem JL, Kerr L, Stuerchler D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 1992; 95:167-179.
5. van Riemsdijk MM, van der Klauw MM, van Heest JA, et al. Neuropsychiatric effects of antimalarials. Eur J Clin Pharmacol 1997; 52:1-6.
6. Ronn AM, Ronne-Rasmussen J, Gotzsche PC, Bygbjerg IC. Neuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: comparing a retrospective and a prospective study. Trop Med Int Health 1998; 3:83-88.
7. Weiss WR, Oloo AJ, Johnson A, et al. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 1995; 171:1569-1575.
8. Miller KD, Lobel HO, Satriale RF, et al. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986; 35:451-458.
9. Hudson AT, Dickins M, Ginger CD, et al. 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp Clin Res 1991; 17:427-435.
10. Fry M, Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy1.4-naphthoquinone (566C80). Biochem Pharmacol 1992; 43:1545-1553.
11. Canfield CJ, Pudney M, Gutteridge WE. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 1995; 80:373-381.
12. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Am J Trop Med Hyg 1999; 60:533-541.
13. Kremsner PG, Looareesuwan S, Chulay JD. Atovaquone and proguanil hydrochloride for treatment of malaria. J Travel Med 1999; 6 (Suppl 1):S18-S20.
14. Glaxo Wellcome. Data on file.
15. Shanks GD, Gordon DM, Klotz FW, et al. Efficacy and safety of atovaquone/proguanil for suppressive prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis 1998; 27: 494-499.
16. Sukwa TY, Mulenga M, Chisaka N, et al. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. AmJ Trop Med Hyg 1999; 60:521-525.
17. Lell B, Luckner D, Ndjave M, et al. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351:709-713.
18. Shapiro TA, Ranasinha CD, Kumar N, Barditch-Crovo P. Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am J Trop Med Hyg 1999; 60:831-836.
19. van der Berg JD, Duvenage CSJ, Roskell NS, Scott TR. Safety and efficacy of atovaquone and proguanil hydrochloride for prophylaxis of Plasmodium falciparum malaria in South Africa. Clin Therap 1999; 21:741-749.
20. Davis JR. Laboratory methods for the conduct of experimental malaria challenge of volunteers. Vaccine 1994; 12 321-327.
21. White NJ. The development of immunity to malaria (a clinical view). Asian Pac J Allergy Immunol 1993; 11:1-3.
22. Looareesuwan S, Viravan C, Webster HK, et al. Clinical studies of atovaquone, alone or in combination with other anti malarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996; 54:62-66.
23. Radloff PD, Philipps J, Hutchinson D, Kremsner PG. Atovaquone plus proguanil is an effective treatment for Plasmodium ovale and P. malariae malaria. Trans R Soc Trop Med 1996; 90:682.
24. Davies CS, Pudney M, Matthews PJ, Sinden RE. The causal prophylactic activity of the novel hydroxynaphthoquinone 566C80 against Plasmodium berghei infections in rats. Acta Leidensia 1989; 58:115-128.
25. Davies CS, Pudney M. Nicholas JC, Sinden RE. The novel hydroxynaphthoquinone 566C80 inhibits the development of liver stages of Plasmodium berghei cultured in vitro. Parasitology 1993; 106:1-6.
26. Fairley NH. Chemotherapeutic suppression and prophylaxis in malaria. An experimental investigation undertaken by research teams in Australia. Trans R Soc Trop Med 1945; 38: 31 -365.
27. Fairley NH. Researches on paludrine (M.4888) in malaria. An experimental investigation undertaken by the L.H.Q. Medical Research Unit (A.I.F), Cairns, Australia. Trans R Soc Trop Med 1946; 40:105-151.
28. Covell G, Nicol WD, Shute PG, Maryon M. "Paludrine" (proguanil) in prophylaxis and treatment of malarial infections, caused by a West African strain of P. Palciparum. BMJ 1949; 1:88-91.
29. Lunn JS, Chin W, Contacos PG, Coatney GR. Cycloguanil pamoate (CI-501) as a causal prophylactic against a Southern Rhodesian strain of falciparum malaria. Am J Trop Med Hyg 1964: 13:783-785.
30. Chiodini PL, Conlon CP, Hutchinson DB, et al. Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. J Antimicrob Chemother 1995;36:1073-1078.
31. Chulay JD. Challenges in the development of antimalarial drugs with causal prophylactic activity. Trans R Soc Trop Med 1998; 92:577-579.
32. Handschin JC, Wall M, Steffen R. Sturchler D. Tolerability and effectiveness of malaria chemoprophylaxis with mefloquine or chloroquine with or without co-medication. J Travel Med 1997; 4:12 1-127.
33. Fleiss JL. Statistical methods for rates and proportions. 2nd Ed. New York: John Wiley & Sons, 1981.
34. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313: 36-39.
35. Lobel HO, Roberts JM, Somaini B, Steffen R. Efficacy of malaria prophylaxis in American and Swiss travelers to Kenya. J Infect Dis 1987; 155:1205-1209.
36. Ohrt C, Richie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997: 126:963-972.
37. El-Sadr WM, Murphy RL, Yurik TM, et al. A randomized trial of atovaquone versus dapsone for the prevention of Pneumocystis carinii pneumonia in patients with humanimmunodeficiency virus infection who are intolerant to trimethoprim and/or sulfomides. N Engl J Med 1998; 339: 1889-1895.
38. Erikkson B, Bjorkman A, Keiau M. How safe is proguanil? A postmarketing investigation of side effects. Scand J Infect Dis 1991; 23:489-493.
39. Tracy J, Webster L. Drugs used in the chemotherapy of malaria. In: Hardman J, Gilman A, Limbird L, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th Ed. New York: McGraw-Hill, 1996: 965-985.
40. Pudney M, Gutteridge W, Zeman A, et al. Atovaquone and prognanil hydrochloride: a review of nonclinical studies. J Travel Med 1999; 6(Suppl 1):S8-S12.
41. Beerahee M. Clinical pharmacology of atovaquone and proguanil hydrochloride. J Travel Med 1999; 6(Suppl 1):S13-S17.